Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Axitinib MeSH Descriptor Data 2025


MeSH Heading
Axitinib
Tree Number(s)
D02.065.277.051
D02.241.223.100.100.115
D02.455.426.559.389.127.085.093
D03.383.129.539.487.065
D03.633.100.449.065
Unique ID
D000077784
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077784
Scope Note
A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.
Entry Term(s)
AG 013736
AG-013736
AG013736
Inlyta
Pharm Action
Antineoplastic Agents
Protein Kinase Inhibitors
Registry Numbers
C9LVQ0YUXG
0
CAS Type 1 Name
Benzamide, N-methyl-2-((3-((E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)-
Public MeSH Note
2019; AXITINIB was indexed under IMIDAZOLES and INDAZOLES 2005-2018
History Note
2019 (2005)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2018/05/21
Axitinib Preferred
AG 013736 Narrower
Inlyta Narrower
page delivered in 0.116s